Dose-dense Weekly Paclitaxel Does Not Increase PFS

Posted on March 3, 2016

Research

(March 3, 2016) In a study published in the New England Journal of Medicine this week, researchers report that a dose-dense weekly paclitaxel regimen failed to improve progression-free survival in advanced ovarian cancer versus a conventional regimen and optional bevacizumab (Avastin).

Patients treated with weekly paclitaxel plus carboplatin had a median PFS of 14.7 months compared with 14.0 months among patients assigned to paclitaxel and carboplatin every 3 weeks. The outcome contrasted with that of a previous Japanese study showing a significant survival benefit in ovarian cancer treated with dose-dense weekly paclitaxel.

Read an article on this study in MedPage Today; and read the study abstract.

Related Topics

OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies

OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies

A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued

OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs

OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs

Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued

OCRA-Funded Research Expands Impact of DNA and RNA Data

OCRA-Funded Research Expands Impact of DNA and RNA Data

A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.